Skip to main content
Top

21-04-2025 | Dementia | Letter to the Editor Free for a limited time

“Body-first” dementia with Lewy bodies

Authors: David S. Goldstein, Courtney Holmes, Patti Sullivan, Risa Isonaka, Dragan Maric, Parvez Alam, Christine Cliatt-Brown, Janna Gelsomino, Sarah Moore, Byron Caughey, Guillaume Lamotte

Published in: Clinical Autonomic Research

Login to get access

Excerpt

According to the synucleinopathy staging schema [1] and the brain-first/body-first theory [10], in Parkinson’s disease (PD) the pathogenetic process can begin outside the brain, with early involvement of the autonomic nervous system. The body-first concept might also apply to the closely related disease dementia with Lewy bodies (DLB) [11]. We report the case of a patient in whom DLB manifested clinically after he had been followed for several years as a participant in the prospective, longitudinal PDRisk study. He underwent comprehensive initial and serial assessments that enabled evaluation of the body-first sequence. It is important to confirm by postmortem analyses whether at-risk individuals who are diagnosed subsequently with DLB have supportive tissue neurochemical and neuropathologic evidence; however, such evidence is highly unusual. Here we report postmortem neurochemical and neuropathological data in the same patient. …
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
“Body-first” dementia with Lewy bodies
Authors
David S. Goldstein
Courtney Holmes
Patti Sullivan
Risa Isonaka
Dragan Maric
Parvez Alam
Christine Cliatt-Brown
Janna Gelsomino
Sarah Moore
Byron Caughey
Guillaume Lamotte
Publication date
21-04-2025
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-025-01128-6

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest